Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Larazotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | NPY2R | P49146 | 7/20 | 0.41 |
| ▸ | NPY4R | P50391 | 7/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.41 |
| ▸ | NPY1R | P25929 | 5/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CTSE | P14091 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | TFPI | P10646 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Larazotide SCHEMBL28795844 | 1.00 | CAPN1 (0.43) | CAPN1STAT3NTSR1NPY2RNPY4R | |
| Larazotide SCHEMBL23668121 | 1.00 | CAPN1 (0.43) | CAPN1STAT3NTSR1NPY2RNPY4R | |
| Larazotide SCHEMBL29366234 | 0.98 | CAPN1 (0.42) | CAPN1STAT3NTSR1NPY2RNPY4R | |
| SCHEMBL30286103 | 0.96 | CAPN1 (0.43) | CAPN1STAT3NTSR1NPY2RNPY4R | |
| SCHEMBL29568037 | 0.91 | CAPN1 (0.42) | CAPN1STAT3NTSR1OPRD1 | |
| SCHEMBL30197449 | 0.89 | CAPN1 (0.44) | CAPN1STAT3NTSR1NPY2RNPY4R | |
| SCHEMBL30539771 | 0.86 | CTSD (0.42) | CAPN1STAT3NTSR1CTSDBACE1 | |
| SCHEMBL29566935 | 0.86 | OPRD1 (0.41) | CAPN1NTSR1OPRD1 | |
| SCHEMBL29567235 | 0.86 | NTSR1 (0.40) | CAPN1STAT3NTSR1OPRD1 | |
| SCHEMBL29567365 | 0.86 | NTSR1 (0.40) | CAPN1STAT3NTSR1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034191-A1 | LARAZOTIDE FORMULATIONS | INTERLUDE BIOPHARMA CO (US) | 2026-02-05 | — | — | US | claimed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | claimed |
| US-20250312463-A1 | AUGMENTED PEPTIDE COMPOSITIONS AND METHODS | Neo7Bioscience, Inc. (US) | 2025-10-09 | — | — | US | claimed |
| US-12414979-B2 | Compositions and methods for treating Sjogren's syndrome | INTERLUDE BIOPHARMA CO. (US) | 2025-09-16 | — | — | US | claimed |
| US-12337024-B2 | Larazotide formulations | INTERLUDE BIOPHARMA CO. (US) | 2025-06-24 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250144166-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RHO KINASE | INTERLUDE BIOPHARMA CO (US) | 2025-05-08 | — | — | US | claimed |
| EP-3946461-B1 | XYLOGLUCAN-CONTAINING PRODRUGS AND METHODS OF MANUFACTURE AND USE THEREOF | UNIV BRITISH COLUMBIA (CA) | 2025-01-15 | — | — | EP | claimed |
| EP-4486366-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2025-01-08 | — | — | EP | claimed |
| EP-4475867-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RHO KINASE | Interlude Biopharma Co. (US) | 2024-12-18 | — | — | EP | claimed |
| WO-2022224059-A1 | ZONULIN ANTAGONISTS FOR THE TREATMENT OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) AND ADULTS (MIS-A) | EBRIS S.R,L, (IT) | 2022-10-27 | — | — | WO | claimed |
| US-20220331392-A1 | LARAZOTIDE FORMULATIONS | INTERLUDE BIOPHARMA CO. | 2022-10-20 | — | — | US | claimed |
| WO-2022192675-A1 | SYNTHETIC SIGNAL PEPTIDES FOR DIRECTING SECRETION OF HETEROLOGOUS PROTEINS IN YEAST | TENZA, INC. (US) | 2022-09-15 | — | — | WO | claimed |
| CN-114832088-A | Application of Larazolid polypeptide in preparation of medicines for relieving adriamycin cardiotoxicity | 李臻 | 2022-08-02 | — | — | CN | claimed |
| EP-4013441-A1 | LARAZOTIDE FORMULATIONS | 9 Meters Biopharma, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| US-20220184220-A1 | XYLOGLUCAN-CONTAINING PRODRUGS AND METHODS OF MANUFACTURE AND USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-06-16 | — | — | US | claimed |
| WO-2022108870-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY FIBROSIS | 9 METERS BIOPHARMA, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| CN-114514031-A | Lalazole peptide preparation | 九米特生物制药有限公司 | 2022-05-17 | — | — | CN | claimed |
| US-20220047668-A1 | COMPOSITIONS AND METHODS FOR TREATING SJOGREN'S SYNDROME | INTERLUDE BIOPHARMA CO. | 2022-02-17 | — | — | US | claimed |
| EP-3946461-A1 | XYLOGLUCAN-CONTAINING PRODRUGS AND METHODS OF MANUFACTURE AND USE THEREOF | The University of British Columbia (CA) | 2022-02-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184220-A1 | XYLOGLUCAN-CONTAINING PRODRUGS AND METHODS OF MANUFACTURE AND USE THEREOF | SI, FUT6, GALE | CAPN1 715/4885STAT3 4665/4885NTSR1 986/4885 |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | ADM2, TAS2R42, ACP1 | CAPN1 437/4885STAT3 2039/4885NTSR1 1911/4885 |
| US-20260034191-A1 | LARAZOTIDE FORMULATIONS | SLC10A2, SLC10A1, GLP1R | CAPN1 3710/4885STAT3 679/4885NTSR1 189/4885 |
| US-20220047668-A1 | COMPOSITIONS AND METHODS FOR TREATING SJOGREN'S SYNDROME | SSB, PDE12, PDE3A | CAPN1 2953/4885STAT3 2634/4885NTSR1 1513/4885 |
| US-12414979-B2 | Compositions and methods for treating Sjogren's syndrome | SSB, PDE12, PDE3A | CAPN1 2953/4885STAT3 2634/4885NTSR1 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.